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Background & aims: Oxidative stress and low antioxidant levels are implicated in the aetiology of
sarcoidosis, an inﬂammatory disease. Quercetin is a potent dietary antioxidant that also displays anti-
inﬂammatory activities. Consequently, the aim is to examine the effect of quercetin supplementation on
markers of oxidative stress and inﬂammation in sarcoidosis.
Methods: A double-blind intervention study has been conducted with two groups of non-smoking, un-
treated sarcoidosis patients, matched for age and gender. One group was given 4x500 mg quercetin
(n ¼ 12) orally within 24 h, the other one placebo (n ¼ 6). Plasma malondialdehyde levels were used as
marker of oxidative damage, plasma ratios of TNFa/IL-10 and IL-8/IL-10 as pro-inﬂammatory markers.
Results: Quercetin supplementation improved the antioxidant defence, indicated by the increased total
plasma antioxidant capacity. Moreover, quercetin supplementation also reduced markers of oxidative
stress and inﬂammation in the blood of sarcoidosis patients. The effects of quercetin supplementation
appeared to be more pronounced when the levels of the oxidative stress and inﬂammation markers were
higher at baseline.
Conclusions: Sarcoidosis patients might beneﬁt from the use of antioxidants, such as quercetin, to reduce
the occurring oxidative stress as well as inﬂammation. The effects of long-term use of antioxidant
supplementation in sarcoidosis, using e.g. quercetin, on improvement of lung function remain to be
investigated. (www.clinicaltrials.gov; NCT-00402623).
 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
Open access under the Elsevier OA license.1. Introduction
Sarcoidosis is a chronic inﬂammatory disease of which the exact
cause still needs to be elucidated. Besides the presence of a chronic
inﬂammatory process, sarcoidosis is also associated with the
occurrence of oxidative stress, i.e. an imbalance between the
production of and the protection against reactive oxygen species
(ROS). This is deduced from increased levels of biomarkers of
oxidative damage such as exhaled ethane1 and both 8-isoprostane2
and oxidized proteins3 in the bronchoalveolar lavage ﬂuid (BALF) ofuid; DLCO, diffusing capacity
e in 1 s; FVC, forced vital
lphide; IL, interleukin; LPS,
nuclear factor kappa-B; RNS,
ies; SSA, sulfosalicyclic acid;
idant capacity; TNFa, tumor
þ31 43 3884149.
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for Clinical Nutrition and Metabolsarcoidosis patients. Recently, we have found that the total anti-
oxidant capacity of sarcoidosis patients is approximately 75% of
that of matched controls4 .
To increase the total antioxidant capacity in chronic diseases
associated with enhanced oxidative stress, such as sarcoidosis,
antioxidant supplementation has gained a lot of interest the past
few years.5 A good candidate for such supplementation could be
the dietary antioxidant quercetin. Indeed, it has recently been
shown that quercetin supplementation effectively increases both
the plasma quercetin concentration and the total plasma antioxi-
dant capacity in healthy volunteers.6,7,8 Moreover, it is known that,
within the ﬂavonoid family, quercetin is the most active scavenger
of reactive oxygen species (ROS) and reactive nitrogen species
(RNS) both in vitro and in vivo.9 For example, the antioxidant
capacity of quercetin is several times that of various endogenous
antioxidants including glutathione and vitamin E10. This can be
explained by the presence of two antioxidant pharmacophores
within the molecule that both have the optimal conﬁguration for
free radical scavenging.11ism.Open access under the Elsevier OA license.
Table 1
Characteristics of the participants.
Quercetin-receiving
group
Placebo-receiving
group
number (m/f) 12 (8/4) 6 (4/2)
age 31e69 (46  3) 34e59 (44  3)
length 158e186 (174  3) 158e182 (175  4)
weight 64e96 (81  3) 69e96 (84  4)
body mass index 23e32 (27  1) 24e35 (28  2)
time since diagnosis 1e10 (5  1) 1e11 (4  2)
biopsy taken yes: 7 no: 5 yes: 4 no: 2
DLCO 55e109 (84  5) 85e107 (91  6)
FEV1 36e133 (96  7) 51e101 (86  7)
FVC 75e128 (104  5) 65e112 (97  7)
chest radiograph stage 0/I/II/III/IV (n) 3/3/3/3/1 2/2/1/1/0
Controls are matched on age and gender and do therefore not signiﬁcantly differ
from the patients regarding these parameters. Age is expressed in year, length in cm,
weight in kg, time since diagnosis in years and DLCO (diffuse capacity of the lung for
carbon monoxide), FEV1 (forced expiratory volume in 1 s) and FVC (forced vital
capacity) in % of the predicted value based on age and gender. Data are expressed as
range (mean  SEM).
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it an excellent candidate for antioxidant supplementation in
sarcoidosis. Foremost, several studies have indicated that quercetin,
both added in vitro and supplemented in vivo, also displays anti-
inﬂammatory effects.4,8,12 Indeed, it is known that this ﬂavonoid is
capable of reducing LPS-induced levels of various pro-inﬂamma-
tory cytokines including TNFa and IL-8, two cytokines known to be
elevated in sarcoidosis.4 Secondly, de Boer et al have demonstrated
that quercetin accumulates in the lungs of rats.13 This ﬁnding
suggests that the ﬂavonoid is expected to exert its positive effects
especially in this organ, which is also primarily involved in
sarcoidosis. Moreover, this speciﬁc tissue distribution of quercetin
correlates well with the observations of Kumar et al that oral
quercetin supplementation offers protection against pulmonary
damage induced by inﬂuenza virus infection in mice.14,15
The combination of its tissue speciﬁc distribution and potent
anti-oxidative as well as anti-inﬂammatory capacities prompted us
to study the effect of quercetin supplementation on in vivomarkers
of oxidative stress and inﬂammation in sarcoidosis patients.
Moreover, tomimic a severe inﬂammatory burden that might occur
by incidental exposure to e.g. dust particles, cigarette smoke or
other triggers, an additional ex vivo LPS challenge was performed in
the blood to study the protecting potential of this quercetin
supplementation.
2. Materials and methods
2.1. Materials
Quercetin and lipopolysaccharide (LPS, E. coli 0.26:B6) were
purchased from Sigma Chemical Co. (St. Louis, USA). RPMI 1640
medium containing L-glutamine was obtained from Gibco (UK).
Human TNFa (7300 pg/ml), human IL-10 (4000 pg/ml) and human
IL-8 (10 ng/ml) were acquired from CLB/Sanquin (Amsterdam, the
Netherlands). All other chemicals were of analytical grade.
3. Methods
3.1. General information
All participating patients were recruited via their own physician.
All participants were fully informed, both written and orally, about
the aim and details of the study and have given their written
informed consent.
The study was carried out at the University Hospital Maastricht
after approval of the protocol by the Medical Ethics Committee of
Maastricht University and the University Hospital Maastricht and
registration of the study at www.clinicaltrials.gov (NCT-00402623).
Based on foodstuff questionnaires, it was concluded that all
participants had comparable dietary habits with an average daily
intake of quercetin of approximately 15 mg. None of the partici-
pants took any medication or vitamin or food supplements either
prior to or during the study. Randomisation occurred by ﬁrst
dividing all participants into trios based on their age and gender
and then by randomly giving placebo treatment to one individual
out of each trio.
3.2. Participants
Eighteen Caucasian non-smoking patients with symptomatic
sarcoidosis (age 45  10, 12 male and 6 female) were enrolled.
Sarcoidosis had been diagnosed based on both clinical features and
bronchoalveolar lavage (BAL) ﬂuid analysis results (data not
shown).16 Moreover, a biopsy conﬁrmation of the disease had been
performed in 11 out of the 18 sarcoidosis patients. The clinicalsymptoms of all patients included respiratory symptoms, i.e. dysp-
nea, coughing and chest pain. None of the participants suffered from
extra-pulmonary involvement of sarcoidosis during the study. The
characteristics of the study population are summarized in Table 1.
3.3. Lung function measurement
Lung functionmeasurements included forced expiratory volume
in 1 s (FEV1), forced vital capacity (FVC) and diffuse capacity of the
lung for carbon monoxide (DLCO). FEV1 and FVC were measured
with a pneumotachograph, DLCO by the single-breath method
(Masterlab, Jaeger, Würzburg, Germany). Values were expressed as
a percentage of those predicted based on age and gender.
3.4. Supplementation study
Prior to the actual supplementation period, participants were
subjected to a two-day wash-out period. During this period, they
were not allowed to consume food rich in ﬂavonoids in general or
quercetin in particular. This food included non-organic onions,
apples, red wine, tea, organic and freshly pressed fruit juices,
berries (e.g. blueberries and elderberries), grapes, cherries, raisins,
parsley, broccoli, cabbage,green beans and tomatoes.17 Participants
also had to minimise the use of herbs and spices during this period.
The wash-out period was followed by a 24-h supplementation
period during which all participants had to take 4 capsules con-
taining either 500 mg quercetin or a placebo. The capsules were
taken throughout the day, i.e. during lunch, during dinner, just
before bedtime and the last during breakfast the followingmorning,
3 h before the second blood withdrawal. Before and after this
supplementation period, venous blood samples were drawn into
EDTA-containing vacutainer tubes (Vacutainer, BectoneDickinson,
Belgium) and kept on ice prior to processing which occurred within
1h after blood collection. During supplementation, the samedietary
restrictions as during the wash-out period were applied.
3.5. Preparation of the blood samples
Blood was aliquoted into eppendorfs for both the ascorbic acid
and the glutathione analysis: for the former 10% trichloric acid
(TCA) was added to the whole blood, whereas 1.3% sulfosalicyclic
acid (SSA) in 10 mM hydrochlorous acid (HCl) was used to preserve
the samples for the latter. Another aliquot of blood was used for the
incubations required for the blood-based cytokine production
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centrifuged (3000 rpm, 50 at 4 C) to obtain plasma. Deproteiniza-
tion of an aliquot of this plasma, using 10% TCA 1:1 followed by
centrifugation (13,000 rpm, 50 at 4 C), was carried out for the
trolox equivalent antioxidant capacity (TEAC) and uric acid (UA)
measurement. All samples were stored at 80 C prior to analysis.
3.6. Determination of total plasma quercetin concentration
Total quercetin (sum of quercetin aglycone and quercetin
glucuronides/sulfates) concentrations in plasma were analysed by
means of HPLC with coulometric array-detection after enzymatic
hydrolysis as described previously.18 30-O-methoxy quercetin (iso-
rhamnetin) and 4’-O-methoxyquercetin (tamarixetin) aglycone
and glucuronides/sulfates were not detected in the plasma.
3.7. Markers of oxidative stress: antioxidant status and
malondialdehyde (MDA) levels
The antioxidant status was evaluated by measuring the total
plasma antioxidant status as well as the plasma levels of the indi-
vidual antioxidants ascorbic acid, uric acid and glutathione as
described previously.19
In short, the trolox equivalent antioxidant capacity (TEAC) was
determined as a measure for the total antioxidant status. A solution
of 20 mM ABTS (2,20-azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid)) and 2.5 mM ABAP (2,20-Azobis-(2-amidinopropane)HCl) was
incubated at 60 C to generate ABTS radicals (ABTS) until the
absorbance at 734 nm was 0.070  0.02. During the experiments,
the ABTS stock solution was protected from light and kept on ice.
The samples were incubated with the ABTS radical solution for
5 min and subsequently the absorbance at 734 nm was measured.
The decrease in absorbance, caused by the antioxidant capacity in
the sample, was measured and related to that of trolox standards.
The TEAC is expressed as mM trolox equivalents. The relative
contribution of uric acid, vitamin C and quercetin to the total TEAC
value is calculated using the TEAC value described for each indi-
vidual antioxidant, i.e. 1, 1 and 6.24 respectively.10
Vitamin C was determined by HPLC upon its oxidation by
ascorbate oxidase to dehydroascorbate. The latter reacted with o-
phenylene diamine to its quinoxaline derivative. A Hypersil BDS
C-18 end-capped column (125  4 mm, particle size 5 mm from
Agilent, Palo Alto, CA, USA) was used with a mobile phase of 0.08 M
phosphate buffer (pH 7.8) and methanol with ﬂuorimetric detec-
tion (355e425 nm).
Uric acid was determined by HPLC using a Hypersil BDS C-18
end-capped column (125  4 mm, particle size 5 mm from Agilent,
Palo Alto, CA, USA) with a mobile phase of 0.1% triﬂuoroacetic acid
(v/v) in water. UV detection was performed at 292 nm.
Total glutathione was determined using a recycling method. To
50 ml of each sample, 100 ml of a solution containing NADPH
(0.4 mM) and 5,50-dithiobis 2-nitrobenzoic acid (0.3 mM) in
phosphate buffer (143 mM, pH 7.4) was added in a 96- well plate.
The reaction was started by adding 50 ml of a solution containing
glutathione reductase (4 U/ml). The increase in absorption at
405 nm was followed in time. This increase was related to that of
calibrators containing GSH.
The determination of MDA levels is based on the formation of
a coloured adduct of MDA with 2-thiobarbituric acid (TBA).20 In
short, 100 ml plasma was added to 900 ml of a reagent (containing
0.12 mol/l TBA, 0.32 mol/l o-phoshoric acid and 0.01% (m/v) EDTA)
and incubated for 1h at 100 C. After cooling, theMDA-productwere
extracted with 500 ml butanol. Thirty ml of the butanol layer was
injected on an HPLC system (Agilent, Palo Alto, CA, USA) equipped
with aﬂuorescence detector, set on excitationwavelength of 532nmand emission wavelength of 553 nm with a Nucleosil C18 column
(150  3.2 mm, particle size 5 mm from Supelco Inc. PA, USA).
Samples were elutedwith 65% (v/v) 25mmol/l phosphate buffer pH
4.8, 35% (v/v) methanol. A calibration curve was constructed using
malonaldehyde bis(diethylacetal) as standard.
3.8. Markers of inﬂammation: basal and LPS-induced levels of
TNFa, IL-8 and IL-10
Both basal and LPS-induced levels of all cytokines were quan-
tiﬁed before and after the supplementation using PeliKine Compact
human ELISA kits (CLB/Sanquin, the Netherlands) as described
previously.21 Consequently, the LPS-induced cytokine production
assay was performed previously.
3.9. Ex vivo LPS-induced cytokine production assay
Blood was collected both before and after quercetin supple-
mentation. Within 1 h after this collection, the blood-based cyto-
kine production assay was performed as described previously.21 To
this extent, blood was aliquoted into 24-well sterile plates and
diluted 1:4 with RPMI 1640 (supplementend with L-glutamine).
Subsequently, 0.1 ng/ml LPS was added to induce cytokine
production and the plates were incubated for 24 h at 37 C in 5%
CO2. Cell-free supernatant ﬂuids were then collected by centrifu-
gation (6000 rpm, 10’at 4 C) and stored at 20 C prior to analysis.
All incubations were performed in triplicate.
3.10. Statistics
In general, the data of both the quercetin and placebo group
have been reduced to the delta(after-before) for each patient after
which the average delta values for each parameter were compared
using a Mann Whitney U test. Only exception to this approach was
the relative contribution of the various antioxidants to the TEAC
value. For this analysis, the absolute individual values within the
quercetin group were evaluated by a Mann Whitney U test.
The relation between either the MDA levels or the basal cyto-
kine production and the effect of the quercetin supplementation on
them has been appraised using Spearman’s rank correlation
coefﬁcient.
All statistical analyses were performed using SPSS 15.0. A one-
tailed probability value (P-value) equal to or less than 0.05 was
considered to be statistically signiﬁcant.
4. Results
Baseline plasma quercetin levels were below the lower limit of
detection of 0.054 mM in all sarcoidosis patients prior to supple-
mentation. After supplementation, the quercetin plasma concen-
tration, reaching an average of 0.27  0.04 mM, could be quantiﬁed
in all patients (Fig. 1).
Endogenous blood glutathione (GSH) levels were unaffected by
supplementation in all patients (Fig. 2A). The total plasma antiox-
idant capacity, i.e. the total sum of all plasma antioxidants that is
expressed as trolox equivalent, was signiﬁcantly enhanced (3%,
P< 0.01) after supplementation in the quercetin-receiving patients
(Fig. 2B).
For the quercetin-receiving group, the relative contribution of
not only the exogenous quercetin but also of the endogenous
antioxidants uric acid and vitamin C to the total plasma antioxidant
status is depicted in Fig. 3. These data reveal that total antioxidant
capacity increased only 0.3% due to the presence of quercetin in the
plasma. Combined with the observation that the total increase due
to quercetin administration was 3%, this ﬁnding suggests that
Fig. 3. The relative contribution of uric acid, vitamin C and quercetin to the total
plasma antioxidant capacity in sarcoidosis patients before and after quercetin
supplementation. Subtraction of these three contributions results in a residual plasma
antioxidant capacity that is signiﬁcantly higher after supplementation (198.9  8.7 mM
before vs 213.9  10.9 mM after). Vitamin C and uric acid levels are unaffected by
supplementation (47.7  4.1 mM before vs 44.7  3.4 mM after and 287.1  18.1 mM
before vs 285.6  16.5 mM after, respectively). Data are expressed as mean  S.E.M
(n ¼ 12). * ¼ P < 0.05 compared to the “before” measurement prior to the quercetin
supplementation.
Fig. 1. The effect of quercetin supplementation on the plasma quercetin concentration
in sarcoidosis patients. Data are individually expressed for all 12 sarcoidosis patients
receiving quercetin and all 6 sarcoidosis patients receiving placebo; light grey bars
represent the mean. *P < 0.05 compared to the “before” measurement prior to the
quercetin supplementation.
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oxidants in plasma, although this indirect effect is relatively small.
Supplementation did not affect the plasma levels of uric acid and
vitamin C (data not shown), indicating that these endogenous
antioxidants are not involved.
Malondialdehyde (MDA), amarker of oxidative damage to lipids,
was signiﬁcantly reduced after supplementation with quercetin
(Fig. 4A). Interestingly, the effect of quercetin supplementation on
the plasma MDA levels was dependent on the levels of this marker
prior to supplementation. This indicates that the higher the MDA
level at baseline, the more pronounced the reduction of this marker
of oxidative stress by quercetin supplementation (Fig. 4B).
The ratios of pro- versus anti-inﬂammatory cytokines TNFa/IL-
10 and IL-8/IL-10 were used as inﬂammatory markers. Basal cyto-
kine levels were used to evaluate the direct anti-inﬂammatory
effects of the quercetin supplementation, while the ex vivo LPS-
induced cytokine levels were analysed to mimic the possible
protective effects of such a supplementation against an additional
inﬂammatory burden. Both the basal and ex vivo LPS-induced TNFa/
IL-10 and IL-8/IL-10 ratios were signiﬁcantly decreased upon
quercetin supplementation (Figs. 5 and 6). Although less
pronounced than for the plasma MDA levels, the effect of quercetin
supplementation on basal TNFa and IL-8 levels also showed some
dependency on these cytokine levels prior to supplementationFig. 2. The effect of quercetin supplementation on blood glutathione (GSH) levels (panel A)
individually expressed for all 12 sarcoidosis patients receiving quercetin and all 6 sarcoidosis
the “before” measurement prior to the quercetin supplementation.(Fig. 7A and B). This indicates that the higher the basal cytokine
production, the more prominent the inhibiting effect of quercetin
on this cytokine level. No such effect of the supplementation could
be observed on either the basal plasma level of the anti-inﬂam-
matory cytokine IL-10 (Fig. 7C) or on any of the LPS-induced cyto-
kine levels (data not shown).
No correlations were found between the increase of the total
quercetin plasma concentration or the increase in total plasma
antioxidant capacity and the effect of supplementation on the
markers of oxidative stress and inﬂammation measured.
In the placebo-receiving group, no signiﬁcant differences were
found between the values before and after supplementation
regarding any of the parameters measured.
5. Discussion
Sarcoidosis is an inﬂammatory disorder in which oxidative
stress appears to be involved,1,2 as indicated by several biomarkers
including a reduced antioxidant capacity. To the best of our
knowledge, this is the ﬁrst study demonstrating a positive effect of
a one day antioxidant supplementation on this reduced antioxidant
capacity in sarcoidosis.and total plasma antioxidant capacity (TEAC) (panel B) in sarcoidosis patients. Data are
patients receiving placebo; light grey bars represent the mean. *P < 0.05 compared to
Fig. 4. The effect of quercetin supplementation on plasma malondialdehyde (MDA) levels (panel A) and the relation between these levels at baseline and the net effect of the
quercetin supplementation hereon (panel B) in sarcoidosis patients. This net effect, i.e. the difference between MDA at baseline versus that after quercetin supplementation, is
plotted (y-axis) against the MDA levels (x-axis). Data in panel A are individually expressed for all 12 sarcoidosis patients receiving quercetin and all 6 sarcoidosis patients receiving
placebo (light grey bars represent the mean). Data in panel B are individually expressed for only the 12 sarcoidosis patients receiving quercetin.
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levels, two markers of inﬂammation, are signiﬁcantly reduced by
the in vivo quercetin supplementation. These ex vivo results are in
agreement with our previous in vitro ﬁndings showing that quer-
cetin decreased LPS-induced TNFa- and IL-8 production when
added to the blood of sarcoidosis patients in the test tube.4 Inter-
estingly, the applied one day quercetin supplementation also
resulted in a signiﬁcant decrease of the ratios of pro- versus anti-
inﬂammatory cytokines TNFa/IL-10 and IL-8/IL-10 as well as of the
plasma levels of the lipid peroxidation product MDA, a marker of
oxidative stress. These results conﬁrm that quercetin is capable
of empowering the compromised antioxidant defence system of
sarcoidosis patients as well as of mitigating the inﬂammation
present in sarcoidosis.
A possible explanation for the anti-inﬂammatory effects of
quercetin can be found in the interplay betweenoxidative stress and
inﬂammation. ROS are directly involved in the occurrence of
oxidative stress. Moreover, ROS are also capable of promoting
inﬂammation by activating the transcription factors nuclear factor
kappa B (NF-kB) and activator protein-1. These transcription factors
induce pro-inﬂammatory cytokines such as TNFa.22 By scavenging
ROS, quercetin might not only offer protection against oxidative
stress, the ﬂavonoid may simultaneously mitigate inﬂammation. It
has been reported that quercetin is capable of inhibiting TNFa
production aswell as TNFa gene expression viamodulation of NF-kB
in humanperipheral bloodmononuclear cells.12 At the same time, it
is known that NF-kB activation will induce radical producingFig. 5. The effect of quercetin supplementation on basal levels of the ratios TNFa/IL-10 (pane
all 12 sarcoidosis patients receiving quercetin and all 6 sarcoidosis patients receiving placebo
prior to the quercetin supplementation.enzymes and thus promote radical formation. Consequently, an
anti-inﬂammatory effect of quercetin that decreases NF-kB activa-
tion will prevent this route of radical formation and will thus also
reduce oxidative stress. This shows that the anti-inﬂammatory and
antioxidant effects of quercetin are intertwined.
During the scavenging of ROS, quercetin is converted into
oxidation products. These products might react with critical sulf-
hydryl groups, thereby impairing vital cellular functions.23,24
However, the level of glutathione (GSH), the most abundant
endogenous thiol, is not affected by supplementation of 4x500 mg
quercetin orally within 24 h. This suggests that GSH levels are easily
sufﬁcient to absorb the reactive oxidation products of quercetin.
This outcome could have been anticipated based on the relatively
low plasma quercetin concentration achieved by the current
supplementation (0.27  0.04 mM) compared to the high cellular
concentrations of GSH (1e10 mM).
Interestingly, the effects of quercetin supplementation appear to
be more pronounced when the baseline levels of MDA, TNFa and
IL-8 are increased. Only when MDA levels are high, quercetin
supplementation reduces this marker of oxidative stress. Similarly,
although to a lesser extent, quercetin supplementation only
reduces the TNFa/IL-10 ratio or the IL-8/IL-10 ratio when the basal
levels of these inﬂammatory markers are enhanced. The extent of
the effect of the applied quercetin supplementation appears to be
greatly dependent on the individual baseline levels of oxidative
stress and inﬂammation in the patient. It was expected that the
extent of the effect also correlated with the quercetin plasma levell A) and IL-8/IL-10 (panel B) in sarcoidosis patients. Data are individually expressed for
; light grey bars represent the mean. *P < 0.05 compared to the “before” measurement
Fig. 6. The effect of quercetin supplementation on ex vivo LPS-induced cytokine production. After LPS stimulation, both the relative ratios of TNFa/IL-10 (panel A) and of L-8/IL-10
(panel B) show a signiﬁcant decrease in the quercetin-receiving group. Data are individually expressed for 11 sarcoidosis patients receiving quercetin and 5 sarcoidosis patients
receiving placebo; light grey bars represent the mean. Results are expressed relative to the cytokine release under stimulation of LPS prior to the supplementation. *P < 0.05
compared to the LPS-induced cytokine production in the control without quercetin.
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demonstrated. The variation in baseline value between the
patients, as well as the strong dependency of the effect on those
baseline values, might have concealed the anticipated correlation
between quercetin plasma level and observed effect.
Our results indicate that beneﬁcial effects of antioxidant
supplementation can only be expected in people with enhanced
oxidative stress or inﬂammation. Although this seems trivial, it is
often not realised and might explain the negative outcome of many
clinical studies where antioxidants were supplied to healthy
subjects.25,26 The present study shows that the baseline value of
oxidative damage and inﬂammation is a major discriminator in the
beneﬁcial effect of antioxidant supplementation.
In several diseases associated with enhanced oxidative stress,
the use of antioxidants, i.e. N-acetyl cystein and lipoic acid, is provenFig. 7. The correlation between basal cytokine levels and the net effect of the quercetin su
(x-axis) is the difference between the non-stimulated cytokine level at baseline versus that
cytokines are TNFa (panel A), IL-8 (panel B) and IL-10 (panel C). Data are individually exprto be clinically beneﬁcial.27 In these antioxidant supplementation
studies, besides having an antioxidant effect, the reduction of the
occurring inﬂammation has also been implicated.27
Recently, it has been demonstrated that Inﬂiximab, a TNFa
antibody, improved lung function in stable pulmonary sarcoid-
osis.28 This ﬁnding is in line with studies regarding the use of
Inﬂiximab in the treatment of other chronic inﬂammatory diseases
such as Bechterew,29 Crohn’s disease30 and rheumatoid arthritis.31
However, the latter studies report an inverse correlation between
the effects of this anti-TNFa therapy and the severity of the
pathologies, i.e. the more severe the disease, the less effective this
anti-TNFa antibody therapy is. This might be due to the limited
capacity of anti-TNFa therapy that was restricted by the use of
a ﬁxed dosing regime independent of the baseline TNFa level. In
the present study, no limitation of the quercetin effect was seen. Inpplementation in sarcoidosis patients on the cytokine levels. The net quercetin effect
after supplementation and is plotted against the cytokine level at baseline (x-axis). The
essed for all 12 sarcoidosis patients receiving quercetin.
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outspoken the markers of oxidative stress and inﬂammation, the
more effectively quercetin reduces these markers, including the
TNFa level.
In conclusion, the present study is the ﬁrst to demonstrate that
supplementing a high dose of the antioxidant quercetin over a 24-h
period reduces markers of oxidative stress and inﬂammation in
sarcoidosis, provided these markers are elevated. However, in
a chronic disorder such as sarcoidosis, supplementation has to
proceed over a much longer time period. The safety, tolerability and
an improvement of lung function associated with long-term use of
quercetin in sarcoidosis remain to be investigated. The current
ﬁndings suggest that strengthening the endogenous antioxidant
shield with the dietary quercetin results not only in more protec-
tion against oxidative damage, but also in an increased defence
against inﬂammation. Interestingly, both the anti-oxidative and
anti-inﬂammatory effects of quercetin appeared to be more
pronounced when the level of respectively the occurring oxidative
stress or inﬂammation is higher at baseline. This observed corre-
lation indicates that beneﬁcial effects of antioxidant supplemen-
tation can especially be expected in people with elevated oxidative
stress and inﬂammation, i.e. patients suffering from a disease of
which the pathology is associated with both processes such as
sarcoidosis.
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